News
This seminar will provide information on the treatment and management of ATTR amyloidosis, as well as a discussion of future directions for research and treatment.…
The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein…
Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome…
This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and…
This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and…
How may carpal tunnel syndrome, numbness in hands or feet, shortness of breath, dizziness, and diarrhea be related to each other? These symptoms could be caused by…
Please join us on March 19th, 2022 from 12:30 PM - 3:30 PM ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologists,…
Intellia will present additional interim clinical data from the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with…
Intellia will present its fourth quarter and full-year 2021 financial results.
* To join the call, U.S. callers should dial 1-833-316-0545 and international…
The Rare Disease Day Symposium at the Quinnipiac Frank H. Netter MD School of Medicine is unique to the state of Connecticut in addition to a global event that…